Results 171 to 180 of about 4,206 (188)

Nusinersen/risdiplam

Reactions Weekly, 2023
openaire   +1 more source

Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients

European Journal of Paediatric Neurology, 2020
Dorottya Czövek
exaly  

Nusinersen treatment response markers

Nature Reviews Neurology, 2022
openaire   +2 more sources

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

Lancet, The, 2016
Richard S Finkel, Claudia A Chiriboga, Jiří Vajsar   +2 more
exaly  

Plecanatide, Nusinersen, and Obeticholic acid

Journal of the American Pharmacists Association, 2017
Daniel A, Hussar, Deborah K, Douglas
openaire   +2 more sources

Nusinersen: A Treatment for Spinal Muscular Atrophy

Annals of Pharmacotherapy, 2019
Debra L Stevens, Cheri K Walker
exaly  

A CSF marker of nusinersen treatment response

Nature Reviews Neurology, 2022
openaire   +2 more sources

Nusinersen/onasemnogene abeparvovec

Reactions Weekly, 2022
openaire   +1 more source

Nusinersen/onasemnogene-abeparvovec

Reactions Weekly, 2020
openaire   +2 more sources

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study

Neuromuscular Disorders, 2019
Darryl C De Vivo, Enrico Bertini, Kathryn J Swoboda   +2 more
exaly